companiesCompany
Sumitomo Pharma (Myovant)
Sumitomo Pharma makes Orgovyx (relugolix), the first oral GnRH antagonist for prostate cancer.
Acquired Myovant Sciences (2023). Relugolix (HERO trial) offers rapid, reversible testosterone suppression without the flare of GnRH agonists and with fewer major cardiovascular events in HERO.